Prognostic significance of serum alkaline phosphatase and lactate dehydrogenase levels in patients with unresectable advanced gastric cancer.
Adenocarcinoma
/ blood
Adult
Aged
Aged, 80 and over
Alkaline Phosphatase
/ blood
Biomarkers, Tumor
/ blood
Bone Neoplasms
/ blood
Female
Follow-Up Studies
Humans
Lactate Dehydrogenases
/ blood
Liver Neoplasms
/ blood
Lymphatic Metastasis
Male
Middle Aged
Prognosis
Retrospective Studies
Stomach Neoplasms
/ blood
Survival Rate
Young Adult
Alkaline phosphatase
Gastric cancer
Lactate dehydrogenase
Prognostic value
Survival
Journal
Gastric cancer : official journal of the International Gastric Cancer Association and the Japanese Gastric Cancer Association
ISSN: 1436-3305
Titre abrégé: Gastric Cancer
Pays: Japan
ID NLM: 100886238
Informations de publication
Date de publication:
07 2019
07 2019
Historique:
received:
22
08
2018
accepted:
06
11
2018
pubmed:
13
11
2018
medline:
31
12
2019
entrez:
13
11
2018
Statut:
ppublish
Résumé
This study evaluated the prognostic value of alkaline phosphatase (ALP) and lactate dehydrogenase (LDH) together with host-related factors in patients with unresectable advanced gastric cancer. The study enrolled 262 patients who received chemotherapy for unresectable advanced gastric cancer at Kochi Medical School from 2007 to 2015. Clinicopathological information and systemic inflammatory response data were analyzed for associations between baseline cancer-related prognostic variables and survival outcomes. The median survival time was significantly lower for patients with high ALP, high LDH, high total bilirubin, high aspartate aminotransferase, high alanine transaminase, high gamma-glutamyltransferase, high creatinine, a Glasgow prognostic score (GPS) of 1 or 2 score compared to GPS 0, higher compared to lower neutrophil to lymphocyte ratio (NLR) 3.9, lower compared to higher prognostic nutrition index 36.1, T3-4 compared to T1-2 tumor and diffuse-type compared to intestinal-type histology. Multivariate survival analysis identified high ALP 322 (HR 1.808; 95% CI 1.015-3.220; P = 0.044), T2-3 (HR 2.622; 95% CI 1.224-5.618; P = 0.013), and diffuse-type gastric cancer (HR 2.325; 95% CI 1.341-4.032; P = 0.003) as significant independent predictors of worse prognosis in the studied group of cancer patients. High level of ALP is an independent, worse prognosis factor for patients receiving chemotherapy for unresectable and recurrent gastric cancer.
Sections du résumé
BACKGROUND
This study evaluated the prognostic value of alkaline phosphatase (ALP) and lactate dehydrogenase (LDH) together with host-related factors in patients with unresectable advanced gastric cancer.
METHODS
The study enrolled 262 patients who received chemotherapy for unresectable advanced gastric cancer at Kochi Medical School from 2007 to 2015. Clinicopathological information and systemic inflammatory response data were analyzed for associations between baseline cancer-related prognostic variables and survival outcomes.
RESULTS
The median survival time was significantly lower for patients with high ALP, high LDH, high total bilirubin, high aspartate aminotransferase, high alanine transaminase, high gamma-glutamyltransferase, high creatinine, a Glasgow prognostic score (GPS) of 1 or 2 score compared to GPS 0, higher compared to lower neutrophil to lymphocyte ratio (NLR) 3.9, lower compared to higher prognostic nutrition index 36.1, T3-4 compared to T1-2 tumor and diffuse-type compared to intestinal-type histology. Multivariate survival analysis identified high ALP 322 (HR 1.808; 95% CI 1.015-3.220; P = 0.044), T2-3 (HR 2.622; 95% CI 1.224-5.618; P = 0.013), and diffuse-type gastric cancer (HR 2.325; 95% CI 1.341-4.032; P = 0.003) as significant independent predictors of worse prognosis in the studied group of cancer patients.
CONCLUSIONS
High level of ALP is an independent, worse prognosis factor for patients receiving chemotherapy for unresectable and recurrent gastric cancer.
Identifiants
pubmed: 30417313
doi: 10.1007/s10120-018-0897-8
pii: 10.1007/s10120-018-0897-8
doi:
Substances chimiques
Biomarkers, Tumor
0
Lactate Dehydrogenases
EC 1.1.-
Alkaline Phosphatase
EC 3.1.3.1
Types de publication
Journal Article
Langues
eng
Sous-ensembles de citation
IM
Pagination
684-691Références
Lancet. 2010 Aug 28;376(9742):687-97
pubmed: 20728210
Gastric Cancer. 2013 Jan;16(1):1-27
pubmed: 22729699
Oncol Lett. 2018 Jun;15(6):8853-8862
pubmed: 29844813
World J Gastroenterol. 2014 Aug 21;20(31):10944-52
pubmed: 25152598
Br J Cancer. 2003 Sep 15;89(6):1028-30
pubmed: 12966420
Br J Cancer. 2011 Feb 15;104(4):726-34
pubmed: 21266974
Lancet Oncol. 2017 Dec;18(12):1579-1589
pubmed: 29111259
J Surg Oncol. 2018 Jun;117(8):1697-1707
pubmed: 29761518
Oncology. 2016;90(6):321-6
pubmed: 27225990
Cancer Res. 1976 Jan;36(1):23-7
pubmed: 2381
Cancer Res. 1979 Nov;39(11):4732-8
pubmed: 498100
Cancer Res. 2011 Nov 15;71(22):6921-5
pubmed: 22084445
Dig Surg. 2012;29(6):503-9
pubmed: 23392422
Oncotarget. 2015 Oct 27;6(33):35087-94
pubmed: 26397228
Int J Colorectal Dis. 2007 Aug;22(8):881-6
pubmed: 17245566
Int J Clin Oncol. 2017 Aug;22(4):740-748
pubmed: 28213742
Cancer Res. 2013 Mar 15;73(6):1934-45
pubmed: 23467613
J Clin Pathol. 2007 Jun;60(6):705-8
pubmed: 16644880
Ann Surg Oncol. 2008 Aug;15(8):2336-44
pubmed: 18521687
Medicine (Baltimore). 2016 Jul;95(27):e4065
pubmed: 27399091
Lancet Oncol. 2009 Nov;10(11):1063-9
pubmed: 19818685
Tumour Biol. 2016 Feb;37(2):1879-87
pubmed: 26323257
Chin J Cancer. 2012 Apr;31(4):197-206
pubmed: 22237040
Anticancer Res. 2001 Jan-Feb;21(1B):617-20
pubmed: 11299815
Gut. 1972 Jul;13(7):513-9
pubmed: 4341740
Oncogene. 2012 Sep 6;31(36):3999-4011
pubmed: 22231450
Lancet Oncol. 2008 Mar;9(3):215-21
pubmed: 18282805
World J Gastroenterol. 2014 May 21;20(19):5679-84
pubmed: 24914328
J Gastrointest Surg. 2011 Aug;15(8):1440-9
pubmed: 21541770
J Clin Oncol. 2006 May 10;24(14):2188-96
pubmed: 16682738
Science. 1956 Feb 24;123(3191):309-14
pubmed: 13298683
Cancer Cell. 2006 Jun;9(6):425-34
pubmed: 16766262